Patents by Inventor David Randolph Anderson

David Randolph Anderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLOPYRIMIDINE ITK INHIBITORS
    Publication number: 20240132505
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: October 24, 2023
    Publication date: April 25, 2024
    Inventors: Eric Jon JACOBSEN, David Randolph ANDERSON, James Robert BLINN, Susan Landis HOCKERMAN, Richard HEIER, Paramita MUKHERJEE
  • SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20240067643
    Abstract: The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Application
    Filed: July 3, 2023
    Publication date: February 29, 2024
    Inventors: David Randolph ANDERSON, Susan Landis HOCKERMAN, James Robert BLINN, Eric Jon JACOBSEN
  • Pyrrolopyrimidine ITK inhibitors
    Patent number: 11820775
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: November 21, 2023
    Assignee: Aclaris Therapeutics, Inc.
    Inventors: Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Susan Landis Hockerman, Richard Heier, Paramita Mukherjee
  • Bicyclic-Fused Heteroaryl or Aryl Compounds
    Publication number: 20230339960
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.
    Type: Application
    Filed: June 28, 2023
    Publication date: October 26, 2023
    Inventors: JOHN DAVID TRZUPEK, KATHERINE LIN LEE, MARK EDWARD BUNNAGE, SEUNGIL HAN, DAVID HEPWORTH, FRANK ELDRIDGE LOVERING, JOHN PAUL MATHIAS, NIKOLAOS PAPAIOANNOU, BETSY SUSAN PIERCE, JOSEPH WALTER STROHBACH, STEPHEN WAYNE WRIGHT, CHRISTOPH WOLFGANG ZAPF, LORI KRIM GAVRIN, ARTHUR LEE, DAVID RANDOLPH ANDERSON, KEVIN JOSEPH CURRAN, CHRISTOPH MARTIN DEHNHARDT, EDDINE SAIAH, JOEL ADAM GOLDBERG, XIAOLUN WANG, HORNG-CHIH HUANG, RICHARD VARGAS, MICHAEL DENNIS LOWE, AKSHAY PATNY
  • Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
    Patent number: 11739086
    Abstract: The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: August 29, 2023
    Assignee: Aclaris Therapeutics, Inc.
    Inventors: David Randolph Anderson, Susan Landis Hockerman, James Robert Blinn, Eric Jon Jacobsen
  • Bicyclic-fused heteroaryl or aryl compounds
    Patent number: 11702424
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: July 18, 2023
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS
    Publication number: 20220372034
    Abstract: The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 24, 2022
    Inventors: Eric Jon JACOBSEN, David Randolph ANDERSON, James Robert BLINN, Paramita MUKHERJEE, Paul CHANGELIAN, Canxin XU
  • PYRROLOPYRIMIDINE ITK INHIBITORS
    Publication number: 20220348579
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: April 21, 2021
    Publication date: November 3, 2022
    Inventors: Eric Jon JACOBSEN, David Randolph ANDERSON, James Robert BLINN, Susan Landis HOCKERMAN, Richard HEIER, Paramita MUKHERJEE
  • DEUTERATED MK2 PATHWAY INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20220288070
    Abstract: The present disclosure provides deuterated pyridinone-pyridinyl compounds and compositions useful in the treatment of p38 MAP Kinase mediated having the structures of Formula (I); wherein the A, B, and R groups are as defined in the detailed description. Methods of inhibition of p38 MAP Kinase activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 15, 2022
    Inventors: David Randolph ANDERSON, Gary Anthony DECRESCENZO
  • Substituted pyrrolopyridines as JAK inhibitors
    Patent number: 11420966
    Abstract: The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: August 23, 2022
    Inventors: Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Paramita Mukherjee, Paul Changelian, Canxin Xu
  • SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS
    Publication number: 20220235043
    Abstract: The present invention relates to new sulfonamide pyrrolopyridine compounds and compositions useful in the treatment of JAK-mediated conditions having the structures of Formula (I), wherein the R groups are as defined in the detailed description. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided. Exemplary indications treated by inhibition of JAK kinase activity include, but are not limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, and Celiac disease.
    Type: Application
    Filed: July 31, 2020
    Publication date: July 28, 2022
    Inventors: David Randolph ANDERSON, Eric Jon JACOBSEN, James Robert BLINN, Susan Landis HOCKERMAN, Paramita MUKHERJEE, Paul CHANGELIAN
  • SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20210284637
    Abstract: The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 16, 2021
    Inventors: David Randolph ANDERSON, Susan Landis HOCKERMAN, James Robert BLINN, Eric Jon JACOBSEN
  • Pyrrolopyrimidine ITK inhibitors
    Patent number: 11021482
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: June 1, 2021
    Assignee: Adaris Therapeutics, Inc.
    Inventors: Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Susan Landis Hockerman, Richard Heier, Paramita Mukherjee
  • Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
    Patent number: 10981906
    Abstract: The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: April 20, 2021
    Assignee: ACLARIS THERAPEUTICS, INC.
    Inventors: David Randolph Anderson, Susan Landis Hockerman, James Robert Blinn, Eric Jon Jacobsen
  • Bicyclic-Fused Heteroaryl or Aryl Compounds
    Publication number: 20200377511
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: August 18, 2020
    Publication date: December 3, 2020
    Applicant: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS
    Publication number: 20200347053
    Abstract: The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Application
    Filed: May 4, 2020
    Publication date: November 5, 2020
    Inventors: Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Paramita Mukherjee, Paul Changelian, Canxin Xu
  • Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
    Patent number: 10800775
    Abstract: The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: October 13, 2020
    Assignee: ACLARIS THERAPEUTICS, INC.
    Inventors: David Randolph Anderson, Susan Landis Hockerman, James Robert Blinn, Eric Jon Jacobsen
  • Bicyclic-fused heteroaryl or aryl compounds
    Patent number: 10793579
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: October 6, 2020
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • PYRROLOPYRIMIDINE ITK INHIBITORS
    Publication number: 20200048262
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: August 12, 2019
    Publication date: February 13, 2020
    Inventors: Eric Jon JACOBSEN, David Randolph ANDERSON, James Robert BLINN, Susan Landis HOCKERMAN, Richard HEIER, Paramita MUKHERJEE
  • PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER
    Publication number: 20190352300
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: April 24, 2019
    Publication date: November 21, 2019
    Applicant: ACLARIS THERAPEUTICS, INC.
    Inventors: Eric Jon Jacobsen, James Robert Blinn, John Robert Springer, Susan Landis Hockerman, David Randolph Anderson